Users of Ozempic and related trendy weight-loss drugs may be more likely to develop a rare form of blindness, researchers are reporting.

The study found that a prescription for Ozempic and other drugs containing the active compound, semaglutide, was associated with an increased risk of NAION, or nonarteritic anterior ischemic optic neuropathy.

It’s a mouthful, but relatively rare, affecting two to 10 in every 100,000 people per year. The blinding eye condition causes sudden and painless but permanent loss of vision in one eye due to insufficient blood flow and oxygen to the optic nerve. It’s sometimes referred to as an “eye stroke” and is a significant cause of blindness among adults.